Bone marrow-derived stem/progenitor cells: their use in clinical studies for the treatment of myocardial infarction

Area of Science:

• Regenerative Medicine
• Cardiovascular Research
• Cellular Biology

Background:

• Clinical trials investigating bone marrow-derived cells for myocardial infarction have been conducted globally over the past six years.
• These studies explored various cell types and quantities, hypothesizing their potential to regenerate damaged heart tissue by forming new endothelial cells or cardiomyocytes.

Purpose of the Study:

• To critically analyze published and ongoing clinical trials on bone marrow-derived cell therapies for myocardial infarction.
• To evaluate the efficacy of these treatments from cellular biology and clinical cardiology perspectives.
• To emphasize cellular types, research designs, and efficacy evaluation methods.

Main Methods:

• In-depth review and critical analysis of clinical trial data published since 2002.
• Examination of ongoing clinical trials in the field.
• Focus on cellular biology and clinical cardiology viewpoints.

Main Results:

• Clinical studies consistently demonstrated the safety of bone marrow-derived cell therapies for myocardial infarction.
• Efficacy data across trials remain inconclusive and difficult to unify due to variations in cell types, numbers, patient status, administration routes, and evaluation criteria.

Conclusions:

• While bone marrow-derived cell therapies show promise and are safe for myocardial infarction, their efficacy requires further clarification.
• Standardization of research designs and efficacy assessment methods is crucial for future trials.
• Continued research is needed to optimize cell-based strategies for cardiac regeneration.